Literature DB >> 19634747

Photodynamic therapy for iatrogenic CNV due to laser photocoagulation in central serous chorioretinopathy.

Mehmet Cakir1, Osman Cekiç, Omer F Yilmaz.   

Abstract

The authors report the result of photodynamic therapy for iatrogenic choroidal neovascularization from focal argon laser photocoagulation in a case with central serous chorioretinopathy. A 45-year-old woman who developed choroidal neovascularization after focal argon laser photocoagulation for chronic central serous chorioretinopathy was treated with ocular photodynamic therapy with verteporfin. Choroidal neovascularization became inactive clinically a month after photodynamic therapy. Fluorescein angiography and optical coherence tomography demonstrated the resolved choroidal neovascularization. Baseline visual acuity improved from 20/40 to 20/20 after photodynamic therapy. The patient's condition remained stable 2 years postoperatively. Photodynamic therapy was beneficial for the outcome of iatrogenic choroidal neovascularization that developed after laser treatment for longstanding central serous chorioretinopathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19634747     DOI: 10.3928/15428877-20096030-10

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  5 in total

1.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

2.  Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy.

Authors:  Yoko Nomura; Ryo Obata; Yasuo Yanagi
Journal:  Jpn J Ophthalmol       Date:  2012-04-20       Impact factor: 2.447

3.  Laser-Induced Choroidal Neovascularizations: Clinical Study of 3 Cases.

Authors:  Wipada Laovirojjanakul; Thuss Sanguansak; Yosanan Yospaiboon; Supat Sinawat; Suthasinee Sinawat
Journal:  Case Rep Ophthalmol       Date:  2017-08-08

4.  Risk Factors and Outcomes of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy.

Authors:  Ga-In Lee; A Young Kim; Se Woong Kang; Soo Chang Cho; Kyu Hyung Park; Sang Jin Kim; Kyung Tae Kim
Journal:  Sci Rep       Date:  2019-03-08       Impact factor: 4.379

5.  Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy: OCT Angiography Findings and Risk Factors.

Authors:  Joon Hyung Yeo; Richul Oh; Yoon Jeon Kim; June-Gone Kim; Young Hee Yoon; Joo Yong Lee
Journal:  J Ophthalmol       Date:  2020-02-07       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.